Just caught something interesting about a biotech stock that's been quietly crushing it this year. Intellia Therapeutics is up 47% YTD, and it's not random - there's actually a solid story behind the move.

The company is backed by Cathie Wood's Ark Invest, which makes sense given Ark's whole thing is betting on disruptive innovation. Intellia is deep into gene editing, which is still pretty frontier stuff in biotech. Their main pipeline candidates are lonvo-z for hereditary angioedema and nex-z for transthyretin amyloidosis - both targeting rare genetic diseases where treatment options are basically non-existent.

Here's where it gets interesting: nex-z had a pretty rough 2025. The FDA put clinical holds on phase 3 trials after a patient death linked to liver failure. Obviously that tanked the stock. But fast forward to now - the FDA just lifted those holds and cleared them to move forward. That's a huge deal. The regulatory recovery is basically the entire reason we're seeing this 47% bounce.

Now here's the thing though - and this is where Cathie Wood investors need to think carefully - we still don't know if nex-z actually caused the liver issues. That's a pretty big unknown hanging over things. The company is being more cautious now, screening out patients with liver problems and monitoring more closely, but the underlying question mark remains.

Gene editing therapies already have this uphill battle with insurers because they're expensive and complex to deliver. Add a potential safety concern on top of that, and suddenly the commercial path gets a lot messier. Intellia does have Regeneron as a partner, which is solid, and the patient population for transthyretin amyloidosis is huge - we're talking hundreds of thousands worldwide. Plus nex-z would be a one-shot treatment if it works, which is genuinely compelling.

But real talk: this is a high-volatility play. The regulatory green light is real, but so are the risks. Cathie Wood's portfolio definitely skews toward this kind of high-risk, high-reward bet. If you're thinking about jumping in after a 47% run, just make sure you're comfortable with the fact that things could still go sideways. Gene editing is still frontier medicine, and frontier medicine doesn't always work out the way we hope.